Discussion P W4 Reply 2

1- Infection is a process in which a pathogenic microorganism invades the body of a susceptible host, multiplies and triggers an inflammatory response. This process can cause tissue damage and manifest clinically as an infectious disease with specific signs and symptoms, depending on the causative agent and the host’s defenses. Colonization, on the other hand, refers to the presence of microorganisms on body surfaces without causing damage or an inflammatory response. The main difference between colonization and infection is that colonization does not generate symptoms or inflammation, while infection involves invasion of sterile tissues, multiplication of the pathogen and activation of the immune system (Rehman, 2023).

An example of colonization is the presence of Staphylococcus aureus on the skin or nostrils without causing disease. In contrast, an example of infection is a urinary tract infection caused by Escherichia coli, where bacteria invade the urinary tract, causing inflammation and symptoms such as painful urination and fever.

2- Infection is initiated when a pathogenic agent, such as a microorganism (virus, bacteria, fungus, protozoan) or a toxin, manages to overcome the natural barriers of the host organism, such as the skin or mucous membranes. This process can occur by direct contact, inhalation, ingestion or through wounds. Once inside the body, the pathogen attaches to host cells through specific interactions between its structures (such as glycoproteins or viral capsids) and cell receptors. Subsequently, it penetrates cells or tissues and begins to replicate or release toxins, triggering an initial nonspecific inflammatory response that includes vasodilation, edema, and the arrival of immune cells such as neutrophils and macrophages to contain the infection (Charles A Janeway et al., 2019).

The usual course of an infection follows several stages: incubation, where the pathogen multiplies without visible symptoms; prodromal phase, characterized by nonspecific symptoms such as fever or malaise; clinical phase, where specific signs of disease appear; and finally, resolution, in which the host recovers, the infection becomes chronic or proves fatal. For example, in a viral respiratory infection such as influenza, the virus enters by inhalation, attaches to airway epithelial cells and begins to replicate, causing fever and cough in the clinical phase before resolving or becoming complicated. In general, the initial inflammatory response can eliminate the invading agent if it is effective. If the infection is not contained at this stage, a specific immune response mediated by T and B lymphocytes is activated, generating antibodies and immunologic memory. In more severe cases, the pathogen may spread through the bloodstream or tissues, causing systemic or chronic infections. Finally, if the agent is eliminated, the organism enters a phase of tissue repair to restore damaged tissues.

3- The course of an infection is determined by a complex interaction between pathogen, host and environmental factors. Pathogen factors include virulence, infectivity and ability to evade the immune system. For example, Mycobacterium tuberculosis can survive within macrophages, which facilitates chronic infections such as tuberculosis. Likewise, viruses such as influenza have a high capacity for mutation, which allows them to evade immune defenses and cause recurrent epidemics. As for host factors, immune status is key: immunocompromised individuals, such as those with HIV, are more susceptible to opportunistic infections such as systemic candidiasis. Chronic conditions (diabetes or renal failure), age (children and the elderly are more vulnerable) and genetic predisposition also play a role. For example, in the case of HIV-1, certain genes related to chemokine receptors may confer partial resistance to progression of infection in individuals without long-term progression (Pugliese et al., 2022).

Finally, environmental factors include sanitation conditions, access to medical care and exposure to vectors. Diseases such as dengue or malaria are more prevalent in tropical regions due to the presence of vectors such as mosquitoes. In summary, these variables determine diverse trajectories: from self-limiting infections (such as influenza) to chronic (tuberculosis) or severe progressive (sepsis).

References

Charles A Janeway, J., Travers, P., Walport, M., & Shlomchik, M. J. (2019). Infectious agents and how they cause disease. In Immunobiology: The Immune System in Health and Disease. 5th edition. Garland Science. https://www.ncbi.nlm.nih.gov/books/NBK27114/

Pugliese, G., Liccardi, A., Graziadio, C., Barrea, L., Muscogiuri, G., & Colao, A. (2022). Obesity and infectious diseases: Pathophysiology and epidemiology of a double pandemic condition. International Journal of Obesity, 46(3), 449–465. https://doi.org/10.1038/s41366-021-01035-6

Rehman, T. (2023). Colonization vs. Infection—What’s the Difference? https://www.askdifference.com/colonization-vs-infection/

Discussion P W4 Reply 1

Infection and colonization are terms used in microbiology to describe an organism present in the human body. Infection is an invasion and multiplication of bacteria or a microorganism within the body that can lead to a disease. Infection can be transmitted in various methods such as airborne droplets (Covid, TB), direct contact and contamination of food and water (Hepatitis A), this microorganism can cause systemic symptoms to the host. Colonization its different from infection because the microorganism is already present inside the host without causing any harm but rather helping the body with digestion and also with absorption of nutrients.

During an infection, the microorganisms can cause damage to tissues, organs, or entire systems of the body. This can lead to symptoms such as fever, pain, inflammation, and other signs of illness (Admin-Infection, 2023). Infections are spread from person to person, poor hygiene and poor infection control practices play an important part in the transition of infections from host to host. Handwashing is the first simple solution to prevent infections. Another way of infection is through poorly perform medical procedures, such as not using aseptic techniques and dirty instruments. Methods of infection include direct contact by physical contact from an infected host, indirect contact by touching contaminated surfaces, airborne transmission like Covid and TB where the bacteria spread through the air and is breathable by the host. Vector -borne transmission are transmitted through bites by infected insects like mosquitos and Malaria, lastly by fecal- oral transmission in the case of Hepatitis A through contaminated food and water and poor hand hygiene. The spread of microorganisms and the development of disease or infection can be influenced by various factors, including the resistance of the microorganism, the susceptibility of the host, and the environment in which transmission occurs (Admin-Infection, 2023).

Factors influencing the course of an infection is healthy immune system that can fight of the infection, genetic factors that will allow for the infection to progress due to generic variations and past family medical history such as cancer, and early recognition in a prompt identification of the infection in order to treat it at its early stages. Contact with a pathogen is followed by variable courses of infectious disease, which are only partly explicable by classical risk factors. The susceptibility to infection is variable, as is the course of disease after infection. In this review, we discuss the extent to which this variation is due to genetic factors of the affected individual (the host) (Schmidt et al., 2022). A comprehensive understanding of host genetics can improve the care of patients with infectious diseases

References

Tkacs, N., Johnson, R., & Herrmann, L. (2022). Advanced Physiology and Pathophysiology: Essentials for Clinical Practice. Springer Publishing Company.

Admin-Infection. (2023, December 7). Infection vs colonization – understanding the difference and its impact on health. Infection Cycle. https://infectioncycle.com/articles/infection-vs-colonization-understanding-the-difference-and-its-impact-on-health

Schmidt, A., Groh, A. M., Frick, J. S., Vehreschild, M. J. G. T., & Ludwig, K. U. (2022, February 25). Genetic predisposition and the variable course of infectious diseases. Deutsches Arzteblatt international. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160423/

NR507 Week 4 Collaboration Response MR

response is needed

Hello everyone, 

Describe the specific pathophysiological processes in SLE that lead to the manifestations observed in your assigned body system. How does SLE affect your assigned body system?

     Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects the pulmonary system mainly through inflammation. Autoantibodies and immune complexes attack lung tissue, causing pleuritis, Interstitial Lung Disease (ILD), and pulmonary hypertension (Shin et al., 2022). Symptoms of pleuritis include acute chest aches and labored breathing. For pulmonary system, scarring and inflammation from ILD induce lung rigidity, which impairs gas exchange. 

Discuss the symptoms and clinical manifestations of SLE on your assigned body system. How do these symptoms impact the client’s function and quality of life? Can changes in your assigned body system affect or be affected by other body systems in clients with SLE?

     Cough, dyspnea, chest pain, and weariness are SLE pulmonary symptoms. These symptoms limit mobility and lower the client’s quality of life, making walking or stair climbing difficult (Depascale et al., 2021). Interstitial lung illness can cause fatigue and reduced exercise tolerance, like chronic hypoxia. Pulmonary changes can be linked to cardiovascular stress in right-sided heart failure patients with pulmonary hypertension. If only the renal, cardiovascular, and immune systems are inflamed, pulmonary changes can increase systemic inflammation. This reciprocal body structure activation worsens SLE treatment. 

Discuss the diagnostic tests used to diagnose SLE-related complications in your body system. What challenges are associated with diagnosing SLE if only looking at your assigned body system?

      Imaging and functional testing are needed to diagnose pulmonary involvement in SLE. High-resolution Computed Tomography (CT) scans or chest X-rays are needed to confirm chest opacities, pleural effusion, or lung fibrosis in suspected interstitial lung disease. Pulmonary Function Tests (PFTs) of lung volume and diffusing capacity can also confirm interstitial lung disease (Zamboti et al., 2021). Diagnosing SLE through the pulmonary system is quite challenging since its symptoms are very much related to asthma.

Explore the current treatments for managing SLE symptoms associated with your assigned body system. What are the goals of these treatments, and how effective are they in mitigating the impact of SLE on the body?

      SLE pulmonary manifestations require inflammation control, lung tissue preservation, and symptom suppression. Corticosteroids like prednisone are anti-inflammatory. Medications like mycophenolate mofetil and azathioprine weaken the immune system. Sildenafil and other vasodilators treat pulmonary hypertension. Continuous oxygen supply is also sometimes required for chronic hypoxic conditions (Agarwal et al., 2021). The main goal of this medicines is to manage the disease and slow its progression but cannot repair the damage. They are effective in a way they protect lung function and minimize SLE’s health impacts. 

References

Agarwal, T., Kazemi, S., Costantini, M., Perfeito, F., Correia, C. R., Gaspar, V., Montazeri, L., De Maria, C., Mano, J. F., Vosough, M., Makvandi, P., & Maiti, T. K. (2021). Oxygen releasing materials: Towards addressing the hypoxia-related issues in tissue engineering. Materials Science and Engineering: C, 122, 111896. https://doi.org/10.1016/j.msec.2021.111896Links to an external site. 

Depascale, R., Del Frate, G., Gasparotto, M., Manfrè, V., Gatto, M., Iaccarino, L., Quartuccio, L., De Vita, S., & Doria, A. (2021). Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: A literature review. Therapeutic Advances in Musculoskeletal Disease, 13, 1–24. https://doi.org/10.1177/1759720x211040696Links to an external site. 

Shin, J. I., Lee, K. H., Park, S., Yang, J. W., Kim, H. J., Song, K., Lee, S., Na, H., Jang, Y. J., Nam, J. Y., Kim, S., Lee, C., Hong, C., Kim, C., Kim, M., Choi, U., Seo, J., Jin, H., Yi, B., & Jeong, S. J. (2022). Systemic lupus erythematosus and lung involvement: A comprehensive review. Journal of Clinical Medicine, 11(22), 6714. https://doi.org/10.3390/jcm11226714Links to an external site. 

Zamboti, C. L., Cristina, A., Garcia, T., Krinski, G. G., Bertin, L. D., Almeida, S., Pimpão, H. A., Fujisawa, D. S., Ribeiro, M. A., Pitta, F., & Camillo, C. A. (2021). Functional performance tests in interstitial lung disease: Impairment and measurement properties. Respiratory Medicine, 184, 106413. https://doi.org/10.1016/j.rmed.2021.106413

Week 4 NR507 Collaboration Cafe response KPM

Need a response 

Good Afternoon Dr. Giner and Classmates my designated system for this discussion is the cardiovascular system, one of my favorites.

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. In the cardiovascular system, this autoimmune response can result in several pathophysiological processes:

  • Pericarditis: Inflammation of the pericardium, the membrane surrounding the heart, is the most common cardiac manifestation in SLE patients. This condition can cause chest pain and may lead to pericardial effusion. 
  • Accelerated Atherosclerosis: SLE is associated with an increased risk of premature atherosclerosis, leading to coronary artery disease. Chronic inflammation and immune complex deposition contribute to endothelial damage, promoting plaque formation. 
  • Libman-Sacks Endocarditis: This nonbacterial form of endocarditis involves the formation of sterile vegetations on heart valves, particularly the mitral and aortic valves. These vegetations can lead to valvular dysfunction and increase the risk of thromboembolic events. 

Cardiovascular involvement in SLE can present with different symptoms like Chest Pain Often resulting from pericarditis, patients may experience sharp, pleuritic chest pain that worsens with deep breaths or lying down. Dyspnea can occur due to pericardial effusion or heart failure secondary to myocarditis or coronary artery disease and  Palpitations with Arrhythmias may arise from myocardial involvement or valvular disease.

These cardiovascular manifestations can significantly impact a patient’s daily functioning and quality of life, leading to reduced exercise tolerance, have chronic pain, and anxiety. In addition, cardiovascular complications can affect renal function by altering hemodynamics or contributing to cerebrovascular events by causing embolisms.

Diagnosing cardiovascular involvement in SLE involves a combination of clinical evaluation and diagnostic testing:

  • Echocardiography is  important and essential for pericardial effusion, valvular vegetations indicative of Libman-Sacks endocarditis, and assessing myocardial function.
  • Electrocardiogram (ECG) is  useful for identifying arrhythmias, conduction Issues, and abnormalities, or signs of myocardial ischemia.
  • Cardiac MRI can provide detailed imaging to assess myocardial inflammation, fibrosis, and pericardial involvement.
  • Coronary Angiography is sometimes indicated when there is suspicion of coronary artery disease to evaluate the extent of atherosclerosis.

Challenges in diagnosing SLE-related cardiovascular complications include the overlap of symptoms with other conditions, such as infections or primary cardiac diseases.

Current Treatments and Management of cardiovascular manifestations in SLE focuses on controlling inflammation, preventing disease progression, and addressing specific cardiac issues:

  • Anti-inflammatory and Immunosuppressive Therapies: Medications such as corticosteroids and immunosuppressants are used to reduce systemic inflammation and autoantibody production,  mitigating cardiovascular involvement. 
  • Hydroxychloroquine: Has been shown to have cardioprotective effects in SLE patients, reducing disease flares and potentially decreasing the risk of thrombosis.
  • Cardiovascular Risk Management: Addressing traditional risk factors through lifestyle modifications, statin therapy for dyslipidemia, antihypertensive treatment, and antiplatelet agents can help prevent atherosclerosis progression.
  • Surgical Interventions: In cases of severe valvular disease due to Libman-Sacks endocarditis, surgical repair or replacement may be necessary.

The goal of these treatments is to control disease activity, prevent organ damage, and improve overall survival. While advancements in therapy have improved outcomes, cardiovascular disease remains a leading cause of morbidity and mortality in SLE patients, highlighting the need for ongoing monitoring and comprehensive care.

References:

 Hopkins Lupus. (n.d.). How lupus affects the cardiovascular system. Johns Hopkins Lupus Center. Retrieved from https://www.hopkinslupus.org/lupus-info/lupus-affects-body/lupus-cardiovascular-system/

Ibrahim, A. M., & Siddique, M. S. (2023). Libman-Sacks Endocarditis. In StatPearls. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK532864/Links to an external site.

Johansson, A., & Gustafsson, J. T. (2022). Systemic lupus erythematosus and cardiovascular disease: Mechanisms and clinical implications. Journal of Internal Medicine, 291(2), 189-208. https://doi.org/10.1111/joim.13557

MedlinePlus. (n.d.). Systemic lupus erythematosus (SLE). U.S. National Library of Medicine. Retrieved from https://medlineplus.gov/ency/article/000435.htm

  • Reply to post from Katia Pena Morales